185 related articles for article (PubMed ID: 30848104)
1. A prospective evaluation of rivaroxaban on haemostatic parameters in apparently healthy dogs.
Evans LA; Tansey C; Wiebe M; Sloan CQ; Patlogar JE; Northcutt S; Murphy LA; Nakamura RK
Vet Med Sci; 2019 Aug; 5(3):317-324. PubMed ID: 30848104
[TBL] [Abstract][Full Text] [Related]
2. The effect of atorvastatin on haemostatic parameters in apparently healthy dogs.
Bonaparte A; Tansey C; Wiebe M; Espinoza HE; Patlogar JE; Murphy LA; Nakamura RK
J Small Anim Pract; 2019 Sep; 60(9):565-570. PubMed ID: 31044427
[TBL] [Abstract][Full Text] [Related]
3. Application of thrombelastography in primary total knee and total hip replacement: a prospective 87 patients study.
Wang C; Liu Q; Sun L; Dai G
Blood Coagul Fibrinolysis; 2019 Sep; 30(6):281-290. PubMed ID: 31369408
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of point-of-care coagulation tests as alternatives to anti-Xa activity for monitoring the anticoagulant effects of rivaroxaban in healthy dogs.
Lynch AM; Ruterbories LK; Griffith EH; Hanel RM; Stablein AP; Brooks MB
J Vet Emerg Crit Care (San Antonio); 2021 Jan; 31(1):18-24. PubMed ID: 33118685
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic monitoring of rivaroxaban in dogs using thromboelastography and prothrombin time.
Bae J; Kim H; Kim W; Kim S; Park J; Jung DI; Yu D
J Vet Intern Med; 2019 May; 33(3):1322-1330. PubMed ID: 30859645
[TBL] [Abstract][Full Text] [Related]
6. Retrospective evaluation of shortened prothrombin time or activated partial thromboplastin time for the diagnosis of hypercoagulability in dogs: 25 cases (2006-2011).
Song J; Drobatz KJ; Silverstein DC
J Vet Emerg Crit Care (San Antonio); 2016 May; 26(3):398-405. PubMed ID: 27074596
[TBL] [Abstract][Full Text] [Related]
7. Assessment of hemostatic changes in a model of acute hemorrhage in dogs.
Lynch AM; deLaforcade AM; Meola D; Shih A; Bandt C; Guerrero NH; Riccó C
J Vet Emerg Crit Care (San Antonio); 2016 May; 26(3):333-43. PubMed ID: 26890726
[TBL] [Abstract][Full Text] [Related]
8. Thromboelastographic Evaluation of Dogs with Acute Liver Disease.
Kelley D; Lester C; Shaw S; de Laforcade A; Webster CR
J Vet Intern Med; 2015; 29(4):1053-62. PubMed ID: 26179169
[TBL] [Abstract][Full Text] [Related]
9. Thromboelastography in cats with cholestatic liver disease.
Kakar N; Daniel G; Fellman C; de Laforcade A; Webster CR
J Feline Med Surg; 2021 Feb; 23(2):160-167. PubMed ID: 32672497
[TBL] [Abstract][Full Text] [Related]
10. Blood acid-base, haematological and haemostatic effects of hydroxyethyl starch (130/0.4) compared to succinylated gelatin colloid infusions in normovolaemic dogs.
Buck RK; Bester L; Boustead KJ; Kadwa AR; Zeiler GE
J S Afr Vet Assoc; 2020 Jun; 91(0):e1-e9. PubMed ID: 32501015
[TBL] [Abstract][Full Text] [Related]
11. Determination of reference intervals for single vial rotational thromboelastometry (ROTEM) parameters and correlation with plasmatic coagulation times in 49 clinically healthy dogs.
Jud Schefer R; Heimgartner L; Stirn M; Sigrist NE
Res Vet Sci; 2020 Apr; 129():129-136. PubMed ID: 31982776
[TBL] [Abstract][Full Text] [Related]
12. Variability of tissue factor-activated thromboelastography and whole blood impedance platelet aggregometry in healthy dogs.
Shropshire SB; Olver CS; Lappin MR
J Vet Emerg Crit Care (San Antonio); 2018 Jul; 28(4):334-339. PubMed ID: 29920913
[TBL] [Abstract][Full Text] [Related]
13. Correlation of plasma coagulation tests and fibrinogen
Enk NM; Kutter APN; Kuemmerle-Fraune C; Sigrist NE
J Vet Intern Med; 2019 Jan; 33(1):132-140. PubMed ID: 30537199
[TBL] [Abstract][Full Text] [Related]
14. [Changes in PT and APTT When Administrating Rivaroxaban, a Direct Inhibitor of Activated Factor X].
Nogi K; Kawasugi K; Matsuzawa M; Okufuji Y; Shimadu C; Miyazawa Y; Furukawa T
Rinsho Byori; 2015 Feb; 63(2):194-200. PubMed ID: 26529970
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulant activity of oral rivaroxaban in healthy dogs.
Conversy B; Blais MC; Dunn M; Gara-Boivin C; Del Castillo JRE
Vet J; 2017 May; 223():5-11. PubMed ID: 28671072
[TBL] [Abstract][Full Text] [Related]
16. Prolonged activated prothromboplastin time and breed specific variation in haemostatic analytes in healthy adult Bernese Mountain dogs.
Nikolic Nielsen L; Wiinberg B; Kjelgaard Hansen M; Jensen AL; Kristensen AT
Vet J; 2011 Oct; 190(1):150-3. PubMed ID: 21035361
[TBL] [Abstract][Full Text] [Related]
17. Hemostatic analysis of dogs naturally envenomed by the African puffadder (Bitis arietans) and snouted cobra (Naja annulifera).
Nagel SS; Schoeman JP; Thompson PN; Wiinberg B; Goddard A
J Vet Emerg Crit Care (San Antonio); 2014; 24(6):662-71. PubMed ID: 25351524
[TBL] [Abstract][Full Text] [Related]
18. A prospective evaluation of oral Yunnan Baiyao therapy on thromboelastographic parameters in apparently healthy cats.
Patlogar JE; Tansey C; Wiebe M; Hybki GC; Trostel T; Murphy LA; Nakamura RK
J Vet Emerg Crit Care (San Antonio); 2019 Nov; 29(6):611-615. PubMed ID: 31625678
[TBL] [Abstract][Full Text] [Related]
19. Activated Partial Thromboplastin Time or Prothrombin Time Prolongation During Rivaroxaban Administration: Clinical Risk Factors and Outcomes Analysis.
Yuan Y; Li X; Qiu F
Clin Appl Thromb Hemost; 2023; 29():10760296231178546. PubMed ID: 37271988
[TBL] [Abstract][Full Text] [Related]
20. Evidence of hypercoagulability in dogs with parvoviral enteritis.
Otto CM; Rieser TM; Brooks MB; Russell MW
J Am Vet Med Assoc; 2000 Nov; 217(10):1500-4. PubMed ID: 11128540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
